Hina Singh1,2, Syed Yusuf Mian1, Alok K Pandey2, Sri Krishna3, Gaurav Anand1,2, K Sony Reddy2,4, Neha Chaturvedi3, Vanndita Bahl1, Nidhi Hans2, Man Mohan Shukla3, Quique Bassat5,6,7, Alfredo Mayor5,6, Kazutoyo Miura8, Praveen K Bharti3, Carole Long8, Neeru Singh3, Virander Singh Chauhan2, Deepak Gaur1,2. 1. Laboratory of Malaria and Vaccine Research, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India. 2. Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India. 3. National Institute for Research in Tribal Health (NIRTH), Jabalpur, Madhya Pradesh, India. 4. School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, Odisha, India. 5. ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. 6. Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique. 7. ICREA, Barcelona, Spain. 8. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville Maryland, USA.
Abstract
BACKGROUND: Targeting multiple key antigens that mediate distinct Plasmodium falciparum erythrocyte invasion pathways is an attractive approach for the development of blood-stage malaria vaccines. However, the challenge is to identify antigen cocktails that elicit potent strain-transcending parasite-neutralizing antibodies efficacious at low immunoglobulin G concentrations feasible to achieve through vaccination. Previous reports have screened inhibitory antibodies primarily against well adapted laboratory parasite clones. However, validation of the parasite-neutralizing efficacy against clinical isolates with minimal in vitro cultivation is equally significant to better ascertain their prospective in vivo potency. METHODS: We evaluated the parasite-neutralizing activity of different antibodies individually and in combinations against laboratory adapted clones and clinical isolates. Clinical isolates were collected from Central India and Mozambique, Africa, and characterized for their invasion properties and genetic diversity of invasion ligands. RESULTS: In our portfolio, we evaluated 25 triple antibody combinations and identified the MSP-Fu+CyRPA+RH5 antibody combination to elicit maximal parasite neutralization against P. falciparum clinical isolates with variable properties that underwent minimal in vitro cultivation. CONCLUSIONS: The MSP-Fu+CyRPA+RH5 combination exhibited highly robust parasite neutralization against P. falciparum clones and clinical isolates, thus substantiating them as promising candidate antigens and establishing a proof of principle for the development of a combinatorial P. falciparum blood-stage malaria vaccine.
BACKGROUND: Targeting multiple key antigens that mediate distinct Plasmodium falciparum erythrocyte invasion pathways is an attractive approach for the development of blood-stage malaria vaccines. However, the challenge is to identify antigen cocktails that elicit potent strain-transcending parasite-neutralizing antibodies efficacious at low immunoglobulin G concentrations feasible to achieve through vaccination. Previous reports have screened inhibitory antibodies primarily against well adapted laboratory parasite clones. However, validation of the parasite-neutralizing efficacy against clinical isolates with minimal in vitro cultivation is equally significant to better ascertain their prospective in vivo potency. METHODS: We evaluated the parasite-neutralizing activity of different antibodies individually and in combinations against laboratory adapted clones and clinical isolates. Clinical isolates were collected from Central India and Mozambique, Africa, and characterized for their invasion properties and genetic diversity of invasion ligands. RESULTS: In our portfolio, we evaluated 25 triple antibody combinations and identified the MSP-Fu+CyRPA+RH5 antibody combination to elicit maximal parasite neutralization against P. falciparum clinical isolates with variable properties that underwent minimal in vitro cultivation. CONCLUSIONS: The MSP-Fu+CyRPA+RH5 combination exhibited highly robust parasite neutralization against P. falciparum clones and clinical isolates, thus substantiating them as promising candidate antigens and establishing a proof of principle for the development of a combinatorial P. falciparum blood-stage malaria vaccine.
Authors: Aida Valmaseda; Eusebio Macete; Augusto Nhabomba; Caterina Guinovart; Pedro Aide; Azucena Bardají; Quique Bassat; Tacilta Nhampossa; Sonia Maculuve; Aina Casellas; Llorenç Quintó; Sergi Sanz; Alfons Jiménez; Gaoqian Feng; Christine Langer; Linda Reiling; K Sony Reddy; Alok Pandey; Chetan E Chitnis; Virander S Chauhan; Ruth Aguilar; John J Aponte; Carlota Dobaño; James G Beeson; Deepak Gaur; Clara Menéndez; Pedro L Alonso; Alfredo Mayor Journal: Clin Infect Dis Date: 2018-02-01 Impact factor: 9.079
Authors: Manoj T Duraisingh; Tony Triglia; Stuart A Ralph; Julian C Rayner; John W Barnwell; Geoffrey I McFadden; Alan F Cowman Journal: EMBO J Date: 2003-03-03 Impact factor: 11.598
Authors: Deepak Gaur; Sanjay Singh; Subhash Singh; Lubin Jiang; Ababacar Diouf; Louis H Miller Journal: Proc Natl Acad Sci U S A Date: 2007-10-30 Impact factor: 11.205
Authors: Jennifer C Volz; Alan Yap; Xavier Sisquella; Jenn K Thompson; Nicholas T Y Lim; Lachlan W Whitehead; Lin Chen; Marko Lampe; Wai-Hong Tham; Danny Wilson; Thomas Nebl; Danushka Marapana; Tony Triglia; Wilson Wong; Kelly L Rogers; Alan F Cowman Journal: Cell Host Microbe Date: 2016-06-30 Impact factor: 21.023
Authors: Alfredo Mayor; Abdul Hafiz; Quique Bassat; Eduard Rovira-Vallbona; Sergi Sanz; Sónia Machevo; Ruth Aguilar; Pau Cisteró; Betuel Sigaúque; Clara Menéndez; Pedro L Alonso; Chetan E Chitnis Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Daniel G W Alanine; Doris Quinkert; Rasika Kumarasingha; Shahid Mehmood; Francesca R Donnellan; Nana K Minkah; Bernadeta Dadonaite; Ababacar Diouf; Francis Galaway; Sarah E Silk; Abhishek Jamwal; Jennifer M Marshall; Kazutoyo Miura; Lander Foquet; Sean C Elias; Geneviève M Labbé; Alexander D Douglas; Jing Jin; Ruth O Payne; Joseph J Illingworth; David J Pattinson; David Pulido; Barnabas G Williams; Willem A de Jongh; Gavin J Wright; Stefan H I Kappe; Carol V Robinson; Carole A Long; Brendan S Crabb; Paul R Gilson; Matthew K Higgins; Simon J Draper Journal: Cell Date: 2019-06-13 Impact factor: 41.582
Authors: Anne S Knudsen; Kasper H Björnsson; Maria R Bassi; Melanie R Walker; Andreas Kok; Bogdan Cristinoi; Anja R Jensen; Lea Barfod Journal: Front Immunol Date: 2021-08-10 Impact factor: 7.561